Carocell Bio is dedicated to developing new therapies for the treatment of serious inflammatory diseases

Carocell Bio is dedicated to developing new therapies for the treatment of serious inflammatory diseases

Carocell Bio is developing novel medicines that have the potential to provide safer and more effective approaches to the management of serious inflammatory diseases, including atopic dermatitis, inflammatory bowel disease and burns

Research is focused on reducing over-activation of the intracellular inflammatory cascade. By therapeutically engaging with this process, it is possible to reduce the release of inflammatory cytokines and other inflammatory molecules and so ease inflammation

Carocell Bio’s therapeutic molecules are short proteins (“peptides”) that are highly selective for mitogen-activated protein kinase (MAPK, p38α), an important component in this intracellular inflammation cascade. Combining these peptides with an established nano-polymer delivery system enhances delivery into the cells. The treatments are designed to be delivered topically rather than systemically and the peptides are simply broken down into amino acids so they are likely to provide a much safer option compared with existing therapies

Download the latest presentation slides

Learn more about our research 

Learn more about investment opportunities

Interview with Mike Davies, CEO

DR. MIKE DAVIES TALKING ABOUT CAROCELL BIO'S WORK

INTERVIEW WITH DR. MIKE DAVIES AT BIOTECH SHOWCASE

UK Office

Carocell Bio Ltd.
Brooks Drive
Cheadle Royal Business Park
Manchester
SK8 3TD

Copyright Carocell Bio Ltd. ^©2020